期刊文献+

急性淋巴细胞白血病患儿血浆血管内皮生长因子及组织因子的测定及其临床意义 被引量:3

Plasma concentrations of vascular endothelial growth factor and tissue factor in children with acute lymphoblastic leukemia
下载PDF
导出
摘要 目的检测血浆血管内皮细胞生长因子(VEGF)和组织因子(TF)在急性淋巴细胞白血病(ALL)患儿中的含量变化并探讨其临床意义。方法用双抗体夹心酶联免疫吸附法检测33例ALL患儿血浆VEGF及TF在不同组别治疗前后含量的变化,并探讨两者之间的相关性及其临床意义。结果与正常对照组相比,ALL初治患儿在治疗前血浆VEGF,TF含量明显增高,两组差异有显著性(均P<0.01)。未缓解组患者化疗前血浆VEGF及TF的含量与缓解组化疗前和对照组相比明显升高,差异有显著性(P<0.05或P<0.01),未缓解组化疗后血浆VEGF和TF的含量无明显下降,与化疗前相比差异无显著性,但明显高于缓解组治疗后患者和对照组(均P<0.01)。血浆VEGF和TF在ALL患儿治疗前后低危、中危和高危组之间其差别具有显著性(均P<0.05)。高危组治疗后血浆VEGF和TF水平下降,与化疗前相比差异无显著性,但仍高于对照组(P<0.01)。ALL初治患儿治疗前血浆VEGF与TF含量的增加呈正相关(r=0.50,P<0.01)。结论VEGF,TF可作为了解ALL病情、观察疗效和判断预后的指标之一。 Objective To detect plasma concentrations of vascular endothelial cell growth factor (VEGF) and tissue factor (TF) in children with acute lymphoblastic leukemia (ALL) and explore their clinical significance in ALL. Methods Thirty-three children with newly diagnosed ALL, including 18 cases of low risk, 7 cases of moderate risk and 8 cases of high risk, were enrolled in this study. Twenty-five patients received a complete remission and 8 cases were in non- remission after conventional remission induction chemotherapy. Plasma concentrations of VEGF and TF in the patients were detected using ELISA before and after treatment. Sixteen healthy children served as normal control group. Results Plasma concentrations of VEGF and TF in ALL patients before treatment were significantly higher than those in normal controls ( P 〈 0.01 ). Plasma concentrations of VEGF and TF in the non-remission group before treatment were significantly higher than those in the remission group ( P 〈0.05 ) and the control group ( P 〈0.01 ). After treatment the plasma concentrations of VEGF and TF in the non-remission group were not significantly reduced and higher than those in the remission and the control groups (P 〈0.01 ). There were significant differences in plasma concentrations of VEGF and TF among the low- risk, moderate-risk and high-risk groups before and after treatment ( P 〈 0.05 ). Plasma concentrations of VEGF and TF in the high risk group were not significantly reduced after treatment and higher than those in the control group ( P 〈0.01 ). A linear correlation was noted between plasma VEGF and TF concentrations in ALL patients before treatment ( r = 0.50, P 〈0.01 ). Conclusions VEGF and TF play an important role in the development of ALL and may be useful to the evaluation of the severity and the outcome in ALL.
出处 《中国当代儿科杂志》 CAS CSCD 2007年第6期526-528,共3页 Chinese Journal of Contemporary Pediatrics
关键词 急性淋巴细胞白血病 血管内皮细胞生长因子 组织因子 儿童 Acute lymphoblastic leukemia Vascular endothelial growth factor Tissue factor Child
  • 相关文献

参考文献9

  • 1Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes [ J ]. Cancer, 2002, 95 (9) : 1923-1930.
  • 2方峻,宋善俊.活化的血液凝固因子Ⅶa和组织因子复合物介导信号传导与肿瘤生长、浸润及转移[J].中华血液学杂志,2002,23(5):279-280. 被引量:15
  • 3Lykke J, Nielsen HJ. The role of tissue factor in coloreetal cancer [J]. EurJ Surg Oucol, 2003, 29 (5) :417-422.
  • 4Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [ J]. Blood, 2000, 96 (6) : 2240-2245.
  • 5Wellmann S, Guschmann M, Griethe W, Eckert C, yon Stackelberg A,Lottaz C, et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF [ J ]. Leukemia, 2004, 18(5) :926-933.
  • 6Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy [ J ]. Science, 2002, 295 (5559) : 1526- 1528.
  • 7Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia [ J ]. Blood, 1999, 94(16) : 3717.
  • 8Yu JL, May L, Klement P, Weitz Jl, Rak J. Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy [ J ]. Semin Thromb Hemost, 2004, 30 (1) : 21-30.
  • 9Nakasaki T, Wada H, Watanabe R, Mori Y, Gabazza EC, Kageyama S, et al. Elevated tissue factor levels in leukemic cell homogehate[J]. Clin Appl Thromb Hemost, 2000, 6 (1) : 14-17.

二级参考文献10

  • 1Frederick R. Rickles,Mamoru Shoji,Keisuke Abe.The Role of the Hemostatic System in Tumor Growth, Metastasis, and Angiogenesis: Tissue factor is a Bifunctional Molecule Capable of Inducing Both Fibrin Deposition and Angiogenesis in Cancer[J].International Journal of Hematology.2001(2)
  • 2Eric C,Elisabet G,Merete W,et al.Binding of factor Ⅶa to tissue factor on keratinocytes induces gene expression[].Journal of Biological Chemistry.2000
  • 3Muller BM,Ruf W.Requirement for binding of catalytically active factorⅧa in tissue factor-dependent experimental metastasis[].The Journal of Clinical Investigation.1998
  • 4Eric C,John-Arne R,Elisabet G,et al.Coagulation factors Ⅶa and Ⅹa induce cell signaling leading to up-regulation of the egr-1 gene[].Journal of Biological Chemistry.1999
  • 5Matthisa R,Wolfram R.Mechanistic coupling of protease signaling and initiation of coagulation by tissuc factor[].Proceedings of the National Academy of Sciences of the United States of America.2001
  • 6Katoka H,Uchino H,Asada Y,et al.Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver[].International Journal of Cancer.1997
  • 7Mueller BM,Reisfeld RA,Edgington TS,et al.Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis[].Proceedings of the National Academy of Sciences of the United States of America.1992
  • 8Seto S,Ondocra H,Kaido T,et al.Tissue factor expression in human colorectal carcinoma: correlation with hepatic melastasis and impact on prognosis[].Cancer.2000
  • 9Zhiwei H,Alan G.Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer[].Proceedings of the National Academy of Sciences of the United States of America.2001
  • 10Taniguchi T,Kakkar AK,Tuddenham EG,et al.Enhanced expression of urokinase receptor induced through the tissue factor-factor Ⅶa pathway in human pancreatic cancer[].Cancer Research.1998

共引文献14

同被引文献29

  • 1Iyer R, Evans AE, Qi x, Ho R, Minturn JE, Zhao H, et al. Lestaurtinib enhances the antitumor efficacy of chemotherapy in mu- fine xenograft models of neumblastoma [ J ]. Clin Cancer Res, 2010, 16(5): 1478-1485.
  • 2Nowicki M, Konwerska A, Ostalska-Nowicka D, Derwich K, Mis-kowiak B, Kondraciuk B, et al. Vascular endothelial growth factor (VEGF)-C-a potent risk factor in children diagnosed with stadium 4 neuroblastoma[ J ]. Folia Histochem Cytobiol, 2008, 46 (4) : 493 -499.
  • 3El-Houseini ME, Abdel-Azim SA, E1-Desouky G1, Abdel-Hady S, E1-Hamad MF, Kamel AM. Clinical significance of vascular endothelial growth factor (VEGF) in sera of patients with pediatric malignancies[J]. J Egypt Natl Canc Inst, 2004, 16(1 ) : 57-61.
  • 4Jakovijevic G, Culic S, Stepan J, Bonevski A, Seiwerth S. Vas- cular endothelial growth factor in children with neuroblastoma: a retrospective analysis [ J]. J Exp Clin Cancer Res, 2009, 28: 143.
  • 5Thiele C J, Li Z, Mckee AE. On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology [ J ]. Clin Cancer Res, 2009, 15(19) : 5962-5967.
  • 6Zhu H, Zheng J, Xiao X, Zheng S, Dong K, Liu J, et al. Envi- ronmental endocrine disruptors promote invasion and metastasis of SK-N-SH human neuroblastoma cells[J]. Oncol Rep, 2010, 23( 1 ) : 129-139.
  • 7Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activatcd microRNA, regulates E-cadherin and cancer metastasis [ J ]. Nat Cell Biol, 2010, 12 (3) : 247- 256.
  • 8Zhang J, Zheng Y, Wang Y, Tong H. The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas [ J ]. J Pediatr Hematol Oncol, 2010, 32(3) : 180-184.
  • 9Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor[ J]. Oncogene, 2002, 25, 21 (32): 4885-4893.
  • 10Roux PP, Dorval G, Boudreau M, Angers-Loustau A, Morris SJ, Makkerh J, et al. K252a and CEP1347 are neuroprotective compounds that inhibit mixed-lineage kinase-3 and induce activation of Akt and ERK[J]. J Biol Chem, 2002, 277(51 ) : 49473-49480.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部